Intepirdine | search
Click here to view Intepirdine news from 60+ newspapers.
Bookmark or Share- Intepirdine Joins the Ranks of Failed Alzheimer’s DrugsGlaxoSmithKline developed intepirdine, formerly SB-742457, through Phase 2, but based on the efficacy results decided to discontinue the drug. GSK sold the rights to Axovant in December 2014 for $5 million. Intepirdine failed in Phase 3. The drug did not improve cognition or activities of daily living in patients with mild to moderate AD.
- ALZ-801 | ALZFORUMALZ-801 is converted to homotaurine in vivo, but is more easily absorbed and lasts longer in the blood than tramiprosate. Tramiprosate was reported to inhibit Aβ42 aggregation into toxic oligomers (Gervais et al., 2007; Kocis et al., 2017). Both ALZ-801 and tramiprosate are metabolized to 3-sulfopranpanoic acid (3-SPA), which is normally found ...
- Intepirdine - ALZFORUMBackground. Originally developed by GSK under the name SB-742457, RVT-101/intepirdine is an antagonist of the serotonin receptor 6 (5-HT)6, a largely CNS-specific member of the serotonin receptor subfamily. The serotonergic neurotransmitter system is impaired as Alzheimer’s develops and progresses, and modulating it is seen as a potential ...
- Masupirdine - ALZFORUMThe new trial is enrolling 375 Alzheimer’s patients with agitation for 12 weeks of 50 or 100 mg daily masupirdine or placebo, against a primary outcome of the Cohen-Mansfield Agitation Inventory. The secondary outcome will be a modified ADCS-CGIC focusing on agitation. Running at 18 sites in the U.S. and Poland, the trial is set to run until ...
- Nelotanserin - ALZFORUMNelotanserin is a serotonin, aka 5HT, 2A receptor inverse agonist. Originally called ADP-125, the compound was developed by Arena Pharmaceuticals as a treatment for insomnia, but failed efficacy measures for this indication in Phase 2. In 2015, Axovant Sciences licensed this compound for development, renamed it nelotanserin, and began ...
More
